About STENTiT
STENTiT is a company based in Eindhoven (Netherlands) founded in 2007 by Bart Sanders. STENTiT has raised $1.94 million across 5 funding rounds from investors including EIT Health, European Union and BOM. STENTiT offers products and services including Resorbable Fibrillated Scaffold (RFS). STENTiT operates in a competitive market with competitors including SMT, InspireMD, Vesper Medical, Endospan and Biosensors International, among others.
- Headquarter Eindhoven, Netherlands
- Founders Bart Sanders
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stentit B.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.94 M (USD)
in 5 rounds
-
Latest Funding Round
$2.7 M (USD), Grant
Sep 01, 2023
-
Investors
EIT Health
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of STENTiT
STENTiT offers a comprehensive portfolio of products and services, including Resorbable Fibrillated Scaffold (RFS).
Provides temporary vascular support to restore blood flow and facilitate artery healing.
People of STENTiT
Unlock access to complete
Unlock access to complete
Funding Insights of STENTiT
STENTiT has successfully raised a total of $1.94M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $2.7 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in STENTiT
STENTiT has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include EIT Health, European Union and BOM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investments are directed by BOM toward early and growth-stage firms.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for STENTiT
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by STENTiT
Investment portfolio details for STENTiT
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - STENTiT
Detailed financials for STENTiT
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stentit Comparisons
Peer comparison for STENTiT
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of STENTiT
STENTiT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SMT, InspireMD, Vesper Medical, Endospan and Biosensors International, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
SMT is recognized as a developer of cardiovascular medical devices.
|
|
| Locked | Locked | Locked |
Proprietary stent systems with bio-stable mesh are developed and commercialized.
|
|
| Locked | Locked | Locked |
Venous stent system is developed for deep vein disease treatment.
|
|
| Locked | Locked | Locked |
Endovascular stent graft systems for aortic aneurysm repair are developed.
|
|
| Locked | Locked | Locked |
Products for interventional cardiology and critical care procedures
|
|
| Locked | Locked | Locked |
Three-dimensional vascular stents for peripheral vascular disease are developed.
|
Detailed competitors of STENTiT
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stentit
Complete news archive for STENTiT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about STENTiT
STENTiT was founded in 2007 and raised its 1st funding round 7 years after it was founded.
STENTiT is headquartered in Eindhoven, Netherlands. It is registered at Eindhoven, Noord-brabant, Netherlands.
Bart Sanders is the current CEO of STENTiT. They have also founded this company.
STENTiT is a funded company, having raised a total of $1.94M across 5 funding rounds to date.
The company was founded in 2007 in Eindhoven, Netherlands, and operates in the medical devices sector focused on cardiovascular treatments. Regenerative endovascular implants are developed to address vascular disorders through a catheter-based approach that restores arteries without invasive surgery. These stents feature a biodegradable supportive porous structure designed for implantation in affected arteries. Leadership includes co-founder and CEO Bart Sanders.
STENTiT offers Resorbable Fibrillated Scaffold (RFS).
STENTiT has 7 investors. Key investors include EIT Health, European Union, BOM, NWO, and NextGen Ventures.